Replies to post #12587 on Inovio Pharmaceuticals Inc (INO)

[Ubertino]

I looked at KITE and didn't see anything remotely similar to INO's DNA vaccines.

Are you spamming or just flying a 'kite'?

[MountainMom]

Please read johan31's post from below. It pretty much says it all on the KITE-INO comparison.

"The comparison of kite to Inovio is apples to oranges. Completely different platforms. Car T cell therapy has had some very good preliminary results a la: UPenn/Novartis CTl019; Kite Pharma KTE-C19 CAR; Cellectis UCART19; Bluebird Bio/Celgene CAR T Cells; Juno Therapeutics 19-28z CAR;.........among others.

This is very personalized therapy (each one unique to the patient), very expensive and very laborious. It can not be mass produced which reduces it's market severely.

Inovio's Syncon platform consists of plasmids that can be mass produced for each indication, very inexpensive, can be transported at room temperature and can be quickly manufactured under classic fermentation process.

They both have very good things to offer but can't reasonably be compared to one another and they both can survive together in the biomedical space because of the different markets targeted..."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107201402